Trial Profile
A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs SER 287 (Primary) ; Vancomycin
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Seres Therapeutics
- 06 Jan 2021 According to a Seres Therapeutics media release, updated results from this study were published in the journal Gastroenterology.
- 06 Jan 2021 Results presented in a Seres Therapeutics media release.
- 04 Aug 2020 Results published in the Gastroenterology